益生菌对溃疡性结肠炎疗效的影响

Study on clinical efficacy of probiotics on ulcerative colitis

目的评价益生菌对溃疡性结肠炎的临床疗效。方法选择60例轻中度溃疡性结肠炎患者,随机分成治疗组和对照组,治疗组应用嗜酸乳杆菌颗粒制剂(乐托尔)联合美沙拉嗪,对照组单用美沙拉嗪,治疗8周,8周后统计临床疗效并对比血清C反应蛋白变化。结果治疗组总有效率(93.3%)高于对照组(83.3%),差异有统计学意义(P<0.05);治疗组8周后血清C-反应蛋白下降幅度(7.46±3.51 mg/L)明显高于对照组(4.62±2.09 mg/L),差异有统计学意义(P<0.05)。结论在轻中度溃疡性结肠炎治疗中,联合应用乐托尔比单用美沙拉嗪治疗临床疗效好。

Objective To evaluate the clinical efficacy of probiotics in treatment of ulcerative colitis.Methods A total of 60 patients with mild to moderate active ulcerative colitis were randomly allocated into trial group and control group.Patients in trial group were given with 5-ASA and Lactobacillus.Patients in control group only received 5-ASA.The therapeutic course lasted for 8 weeks.The clinical efficacy and serum level of C-reactive protein were measured before and after treatment.Results After 8 weeks,the total efficacy（93.3%） of patients in trial group was significantly better than that of patients in control group（83.3%） and the decrease in serum level of C-reactive protein in patients of trial group（7.46 ±3.51 mg/L） was significantly higher than that of patients in another group（4.62 ±2.09 mg/L）.Conclusion The clinical efficacy of 5-ASA in combination with Lactobacillus is substantially better than that of 5-ASA alone.